Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, Sucker A, Hillen U, Badenas C, Malvehy J, Zimmer L, Scherag A, Puig S, Schadendorf D. Griewank KG, et al. Among authors: moller i. J Natl Cancer Inst. 2014 Sep 13;106(9):dju246. doi: 10.1093/jnci/dju246. Print 2014 Sep. J Natl Cancer Inst. 2014. PMID: 25217772 Free PMC article.
Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL, Horn S, Murali R, Möller I, Sucker A, Sondermann W, Stiller M, Schilling B, Livingstone E, Zimmer L, Reis H, Metz CH, Zeschnigk M, Paschen A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG. Scholz SL, et al. Among authors: moller i. Oncotarget. 2015 Sep 22;6(28):25868-82. doi: 10.18632/oncotarget.4665. Oncotarget. 2015. PMID: 26327518 Free PMC article.
Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.
Scholz SL, Thomasen H, Reis H, Möller I, Darawsha R, Müller B, Dekowski D, Sucker A, Schilling B, Schadendorf D, Steuhl KP, Paschen A, Westekemper H, Meller D, Griewank KG. Scholz SL, et al. Among authors: moller i. Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5854-61. doi: 10.1167/iovs.15-17469. Invest Ophthalmol Vis Sci. 2015. PMID: 26348634
Oncogene status as a diagnostic tool in ocular and cutaneous melanoma.
Griewank KG, Schilling B, Scholz SL, Metz CH, Livingstone E, Sucker A, Möller I, Reis H, Franklin C, Cosgarea I, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zimmer L. Griewank KG, et al. Among authors: moller i. Eur J Cancer. 2016 Apr;57:112-7. doi: 10.1016/j.ejca.2016.01.010. Epub 2016 Feb 23. Eur J Cancer. 2016. PMID: 26918736
Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi.
Jansen P, Cosgarea I, Murali R, Möller I, Sucker A, Franklin C, Paschen A, Zaremba A, Brinker TJ, Stoffels I, Schadendorf D, Klode J, Hadaschik E, Griewank KG. Jansen P, et al. Among authors: moller i. Cancers (Basel). 2019 Apr 16;11(4):546. doi: 10.3390/cancers11040546. Cancers (Basel). 2019. PMID: 30995742 Free PMC article.
Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A, Murali R, Jansen P, Möller I, Sucker A, Paschen A, Zimmer L, Livingstone E, Brinker TJ, Hadaschik E, Franklin C, Roesch A, Ugurel S, Schadendorf D, Griewank KG, Cosgarea I. Zaremba A, et al. Among authors: moller i. Eur J Cancer. 2019 Sep;119:66-76. doi: 10.1016/j.ejca.2019.07.008. Epub 2019 Aug 14. Eur J Cancer. 2019. PMID: 31419753 Free PMC article.
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM, Chorti E, Matull J, Murali R, Zaremba A, Lodde G, Jansen P, Richter L, Kretz J, Möller I, Sucker A, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Paschen A, Livingstone E, Zimmer L, Schadendorf D, Hadaschik E, Ugurel S, Griewank KG. Thielmann CM, et al. Among authors: moller i. Eur J Cancer. 2021 Dec;159:113-124. doi: 10.1016/j.ejca.2021.09.035. Epub 2021 Nov 4. Eur J Cancer. 2021. PMID: 34742158 Free PMC article.
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM, Matull J, Zaremba A, Murali R, Chorti E, Lodde G, Jansen P, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Kretz J, Möller I, Sucker A, Paschen A, Livingstone E, Zimmer L, Hadaschik E, Ugurel S, Schadendorf D, Griewank KG. Thielmann CM, et al. Among authors: moller i. Eur J Cancer. 2022 Jan;161:99-107. doi: 10.1016/j.ejca.2021.11.009. Epub 2021 Dec 20. Eur J Cancer. 2022. PMID: 34936949 Free PMC article.
501 results